INS and Duchenne muscular dystrophy: We have previously shown that treatment with the glycogen synthase kinase 3β (GSK3) inhibitor, tideglusib, improves muscle quality, function, and insulin sensitivity in the DBA/2J (D2) <i>mdx</i> mouse model of DMD.